Actinium Pharmaceuticals (ATNM) Price & Analysis

Compare

2,256 Followers

ATNM Stock Chart & Stats

$1.51

-$0.06(-4.32%)

At close: Jan 08 4:00 PM EST

$1.51

-$0.06(-4.32%)

Day’s Range― - ―

52-Week Range$1.03 - $2.41

Previous CloseN/A

Volume63.23K

Average Volume (3M)208.30K

Market Cap

$42.11M

Enterprise Value-$32.02M

Total Cash (Recent Filing)$53.39M

Total Debt (Recent Filing)$1.14M

Price to Earnings (P/E)―

Beta1.78

Next Earnings

Mar 13, 2026

EPS Estimate

-0.18

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.16

Shares Outstanding31,195,890

10 Day Avg. Volume380,172

30 Day Avg. Volume208,296

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)1.16

Price to Sales (P/S)0.00

P/FCF Ratio-1.15

Enterprise Value/Market Cap-0.76

Enterprise Value/Revenue-355.82

Enterprise Value/Gross Profit43.93

Enterprise Value/Ebitda0.95

Forecast

1Y Price Target

$4.50

Price Target Upside198.01% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentActinium is developing targeted radiotherapies to deliver cancer-killing radiation with cellular-level precision to treat patients with high unmet need.

Financial PerformanceActinium reported financial results exceeding both analyst and consensus estimates, ending the quarter with approximately $53.4 million.

Preclinical DataATNM-400 has shown encouraging activity in lung and prostate cancer, with breast cancer now added as another solid-tumor target.

Bears Say

Actinium Pharmaceuticals News

Actinium Pharmaceuticals announces preclinical data for ATNM-400

Actinium Pharmaceuticals (ATNM) announced preclinical data for ATNM-400, a first-in-class Actinium-225 antibody radioconjugate, in hormone receptor positive, HER2...

1d ago

ATNM

Actinium Pharmaceuticals Holds Annual Stockholders Meeting

An update from Actinium Pharmaceuticals ( ($ATNM) ) is now available. On November 26, 2025, Actinium Pharmaceuticals held...

6d ago

ATNM

Actinium Pharmaceuticals: Promising Developments in Targeted Radiotherapies and Strong Financial Position Support Buy Rating

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Actinium Pharmaceuticals and keeping the price target...

13d ago

ATNM

Actinium Pharmaceuticals: Promising Developments and Strong Financial Health Support Buy Rating

Actinium Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from...

15d ago

ATNM

Actinium Pharmaceuticals: Promising Developments in Targeted Radiotherapies Drive Buy Rating

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Actinium Pharmaceuticals, retaining the price target of...

27d ago

ATNM

Actinium Pharmaceuticals: Promising Preclinical Success and Innovative Radiotherapy Developments Drive Buy Rating

Actinium Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from...

1M ago

ATNM

Actinium Pharmaceuticals’ ATNM-400 shows superior anti-tumor activity

Actinium Pharmaceuticals (ATNM) announced the presentation of the first ever preclinical data of ATNM-400 in non-small cell lung...

1M ago

AZN

JNJ

Actinium Pharmaceuticals’ ATNM-400: A Promising Radiotherapeutic Advancing Oncology Treatment Options

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals, retaining the price target of...

1M ago

ATNM

Actinium presents preclinical data for ATNM-400

Actinium Pharmaceuticals (ATNM) highlighted new preclinical data for ATNM-400, its novel, first-in-class antibody radioconjugate armed with the potent...

1M ago

ATNM

Promising Pipeline and Strategic Developments Drive Buy Rating for Actinium Pharmaceuticals

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Actinium Pharmaceuticals and keeping the price target...

2M ago

ATNM

Actinium Pharmaceuticals to announces preclinical data from ATNM-400 program

Actinium Pharmaceuticals (ATNM) announced that the first-ever preclinical data from its ATNM-400 program in non-small cell lung cancer...

2M ago

ATNM

Actinium Pharmaceuticals’ New AML Treatment Study: A Potential Game Changer

Actinium Pharmaceuticals (($ATNM)) announced an update on their ongoing clinical study. Study Overview: Actinium Pharmaceuticals is conducting a...

3M ago

ATNM

Actinium Pharmaceuticals: Promising Advancements in Radiopharmaceutical Pipeline Drive Buy Rating

Maxim Group analyst Jason McCarthy has maintained their bullish stance on ATNM stock, giving a Buy rating yesterday....

4M ago

ATNM

Actinium Pharmaceuticals: Promising Pipeline and Strong Financials Drive Buy Rating

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals, retaining the price target of...

4M ago

ATNM

ATNM FAQ

What was Actinium Pharmaceuticals’s price range in the past 12 months?

Actinium Pharmaceuticals lowest stock price was $1.03 and its highest was $2.41 in the past 12 months.

What is Actinium Pharmaceuticals’s market cap?

Actinium Pharmaceuticals’s market cap is $42.11M.

When is Actinium Pharmaceuticals’s upcoming earnings report date?

Actinium Pharmaceuticals’s upcoming earnings report date is Mar 13, 2026 which is in 101 days.

How were Actinium Pharmaceuticals’s earnings last quarter?

Actinium Pharmaceuticals released its earnings results on Nov 24, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.02.

Is Actinium Pharmaceuticals overvalued?

According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Actinium Pharmaceuticals pay dividends?

Actinium Pharmaceuticals does not currently pay dividends.

What is Actinium Pharmaceuticals’s EPS estimate?

Actinium Pharmaceuticals’s EPS estimate is -0.18.

How many shares outstanding does Actinium Pharmaceuticals have?

Actinium Pharmaceuticals has 31,195,890 shares outstanding.

What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?

Actinium Pharmaceuticals reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went up 3.008%.

Which hedge fund is a major shareholder of Actinium Pharmaceuticals?

Currently, no hedge funds are holding shares in ATNM

Actinium Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-133.09%

Trailing 12-Months

Asset Growth

-29.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Actinium Pharmaceuticals

Actinium Pharmaceuticals (ATNM) is a biopharmaceutical company specializing in the development of targeted therapies for patients with unmet needs in oncology. The company primarily focuses on developing radioimmunotherapy and other innovative treatments that leverage its expertise in radioisotopes and antibody technology. Actinium's core products are centered around its proprietary Antibody Radiation-Conjugate (ARC) platform, which aims to deliver potent radiation directly to cancer cells while sparing healthy tissue.

Actinium Pharmaceuticals (ATNM) Earnings & Revenues

Historic Earnings Reports

ATNM Stock 12 Month Forecast

Average Price Target

$4.50

▲(198.01% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","2":"$2","4":"$4","6":"$6","8":"$8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.43,1.7046153846153846,1.9792307692307691,2.253846153846154,2.5284615384615385,2.8030769230769232,3.077692307692308,3.3523076923076927,3.6269230769230774,3.901538461538462,4.176153846153847,4.4507692307692315,4.725384615384615,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.43,1.666153846153846,1.9023076923076923,2.1384615384615384,2.374615384615385,2.6107692307692307,2.846923076923077,3.0830769230769235,3.3192307692307694,3.5553846153846154,3.7915384615384617,4.027692307692308,4.2638461538461545,{"y":4.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.43,1.6276923076923078,1.8253846153846154,2.023076923076923,2.220769230769231,2.4184615384615387,2.6161538461538463,2.8138461538461543,3.0115384615384615,3.2092307692307696,3.406923076923077,3.6046153846153848,3.802307692307693,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.62,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >